Skip to main content
HLB INC. logo

HLB INC. — Investor Relations & Filings

Ticker · 028300 ISIN · KR7028300002 KO Manufacturing
Open in API
Filings indexed 553 across all filing types
Latest filing 2025-08-13 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 028300

About HLB INC.

https://www.hlb.global/

HLB INC. is a biopharmaceutical company focused on developing new global anti-cancer drugs. The company's core activities center on advancing a pipeline of novel therapeutics through its worldwide network, which includes subsidiaries like Elevar Therapeutics and Immunomic Therapeutics. In addition to its primary focus on oncology, HLB's affiliated companies are involved in other life science areas, such as developing and manufacturing in vitro diagnostic medical devices, peptide-based biomaterials, and quasi-drugs. The group also has operations in composite materials and shipbuilding, reflecting its diversified origins.

Recent filings

Filing Released Lang Actions
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for HLB Co., Ltd., covering the period from January 1, 2025, to June 30, 2025. It contains detailed corporate information, financial data, management discussions, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, but the report itself. H1 2025
2025-08-13 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange). It specifically details the 'Correction' (정정신고) of a previously announced merger decision, explicitly stating that the merger between HLB and HLB Life Science has been cancelled due to the exercise of appraisal rights exceeding the agreed threshold. Since this document details a significant corporate event (M&A cancellation) and is a formal regulatory filing, it falls under the M&A Activity category.
2025-08-01 Korean
기타경영사항(자율공시) (회사합병결정 철회에 관한 사항)
M&A Activity Classification · 1% confidence The document is an official announcement from HLB regarding the withdrawal of a previously announced merger decision with HLB Life Science. The text explicitly details the reasons for the cancellation (excessive exercise of appraisal rights by shareholders) and the formal board resolution date. Since this document pertains to the cancellation of a merger/takeover bid, it falls under the M&A Activity category.
2025-08-01 Korean
철회신고서
M&A Activity Classification · 1% confidence The document is a 'Withdrawal Statement' (철회신고서) filed with the Financial Services Commission (금융위원회) regarding the cancellation of a merger between HLB and HLB Life Science. Since the document details the termination of a previously announced merger/takeover activity due to financial conditions (shareholder appraisal rights), it falls under M&A activity-related disclosures. Given the specific nature of cancelling a merger, it is classified as M&A Activity (TAR).
2025-08-01 Korean
전환가액의조정
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from HLB regarding the adjustment of the conversion price for convertible bonds (39th series). It details the change in conversion price due to a decline in market price, the calculation methodology, and the resulting change in the number of convertible shares. This type of disclosure is a standard capital structure update related to financing instruments, which falls under the 'Capital/Financing Update' category.
2025-07-16 Korean
전환가액의조정 (제38회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from HLB regarding the adjustment of the conversion price for its 38th series of convertible bonds (CB). It details the change in conversion price due to a decline in market price, the calculation methodology, and the resulting change in the number of convertible shares. This type of disclosure is a standard corporate action related to capital structure and financing instruments. Since it specifically concerns the adjustment of conversion terms for existing debt securities, it falls under the 'Capital/Financing Update' category.
2025-06-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.